Volume 3, Issue 1 (3-2021)
Tabari Biomed Stu Res J 2021, 3(1): 32-39 |
Back to browse issues page
1- Department of Clinical Pharmacy, Faculty of pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
2- Department of Toxicology, Faculty of pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
2- Department of Toxicology, Faculty of pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Abstract:
The Novel Coronavirus Disease 2019 (COVID-19) was identified firstly in CHINA. Manifestation of this disease can be in wide range from asymptomatic to severe critical disease. All gender and ages are at risk for Covid-19 infection in other hand, COVID-19 was known as respiratory infectious disease but this infection may present with other organ injury.
Although effective drug for COVID-19 treatment not approved but some antiviral agents and immune modulating treatments may be beneficial. The aim of this study is to evaluate the medications using for treatment patients with Covid-19 infection. Although effective treatment not approved for covid-19 but Remdesivir, as antiviral agent, and dexamethasone are recommended for use in hospitalized patients.
Although effective drug for COVID-19 treatment not approved but some antiviral agents and immune modulating treatments may be beneficial. The aim of this study is to evaluate the medications using for treatment patients with Covid-19 infection. Although effective treatment not approved for covid-19 but Remdesivir, as antiviral agent, and dexamethasone are recommended for use in hospitalized patients.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |